BR0111135A - Utilização de uma cepa bacteriana de espécie l. casei - Google Patents

Utilização de uma cepa bacteriana de espécie l. casei

Info

Publication number
BR0111135A
BR0111135A BR0111135-3A BR0111135A BR0111135A BR 0111135 A BR0111135 A BR 0111135A BR 0111135 A BR0111135 A BR 0111135A BR 0111135 A BR0111135 A BR 0111135A
Authority
BR
Brazil
Prior art keywords
married
species
bacterial strain
composition
food
Prior art date
Application number
BR0111135-3A
Other languages
English (en)
Inventor
Eric Postaire
Benjamin Bonavida
Original Assignee
Gervais Danone Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8850597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0111135(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gervais Danone Sa filed Critical Gervais Danone Sa
Publication of BR0111135A publication Critical patent/BR0111135A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/125—Casei
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/245—Lactobacillus casei

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"UTILIZAçãO DE UMA CEPA BACTERIANA DE ESPéCIE L. CASEI". A invenção refere-se à utilização de Lactobacillus casei em uma composição administrável por via oral para reforçar a imunidade específica frente aos microorganismos patógenos. Esta composição pode ser particularmente um alimento ou complemento alimentício.
BR0111135-3A 2000-05-25 2001-04-27 Utilização de uma cepa bacteriana de espécie l. casei BR0111135A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0006679A FR2809312B1 (fr) 2000-05-25 2000-05-25 Utilisation de l. casei dans des compositions immunostimulantes
PCT/FR2001/001310 WO2001089541A1 (fr) 2000-05-25 2001-04-27 Utilisation de lactobacillus casei dans des peptides immunostimulantes

Publications (1)

Publication Number Publication Date
BR0111135A true BR0111135A (pt) 2003-04-08

Family

ID=8850597

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111135-3A BR0111135A (pt) 2000-05-25 2001-04-27 Utilização de uma cepa bacteriana de espécie l. casei

Country Status (27)

Country Link
US (1) US7604809B2 (pt)
EP (1) EP1283714B1 (pt)
JP (1) JP2003534284A (pt)
CN (1) CN1194707C (pt)
AR (1) AR028626A1 (pt)
AT (1) ATE332143T1 (pt)
AU (2) AU5643501A (pt)
BG (1) BG65884B1 (pt)
BR (1) BR0111135A (pt)
CA (1) CA2410350C (pt)
CZ (1) CZ303600B6 (pt)
DE (1) DE60121327T2 (pt)
DK (1) DK1283714T3 (pt)
EA (1) EA005081B1 (pt)
ES (1) ES2267763T3 (pt)
FR (1) FR2809312B1 (pt)
HR (1) HRP20020935A2 (pt)
HU (1) HUP0302041A3 (pt)
IL (1) IL152980A0 (pt)
MA (1) MA25760A1 (pt)
MX (1) MXPA02011636A (pt)
NO (1) NO332369B1 (pt)
PL (1) PL201801B1 (pt)
PT (1) PT1283714E (pt)
SK (1) SK18272002A3 (pt)
WO (1) WO2001089541A1 (pt)
ZA (1) ZA200209087B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
GB0009294D0 (en) 2000-04-15 2000-05-31 Sec Dep For The Home Departmen Improvements in and relating to analysis of DNA samples
US9610347B2 (en) * 2001-04-30 2017-04-04 Cortcontrol Vaccination response for immunodeficiency or high cortisol
CN1317385C (zh) * 2003-05-30 2007-05-23 上海光明乳业股份有限公司 干酪乳杆菌Bd－II菌株及其在降低血脂方面的应用
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
PT1629850E (pt) * 2004-08-24 2007-08-14 Nutricia Nv Composição nutricional que compreende a administração de oligossacarídeos indigeríveis
WO2006064449A1 (en) * 2004-12-15 2006-06-22 Van Der Westhuizen Cornelis Fl Detoxifying and immunity-booster composition
EP1683425A1 (en) * 2005-01-21 2006-07-26 Compagnie Gervais Danone Use of a fermented milk containing L. Casei for the manufacture of a composition for the prevention or treatment of a delayed-type hypersensitivity reaction
ES2264368B1 (es) * 2005-02-11 2007-12-01 Francisco Exposito Mesa Complemento alimenticio o dietetico compuesto por productos procedentes del lisado de microorganismos.
BRPI0611493B1 (pt) 2005-05-31 2022-04-05 Alimentary Health Ltd. Lactobacilos probióticos felinos
PL1885383T3 (pl) 2005-05-31 2017-06-30 Iams Europe B.V. Kocie probiotyczne bifidobakterie
PT2073842E (pt) 2006-09-10 2015-04-07 Glycotope Gmbh Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos
FR2912657B1 (fr) * 2007-02-16 2009-04-17 Gervais Danone Sa Utilisation de lactobacillus casei pour renforcer la protection induite par la vaccination anti-grippale.
WO2009021585A1 (en) * 2007-08-13 2009-02-19 Dsm Ip Assets B.V. Probiotic bacteria for rducing the occurence of symptoms of winter infections
WO2009067000A1 (en) * 2007-11-20 2009-05-28 N.V. Nutricia Composition with synbiotics
EP2119365B1 (de) 2008-05-13 2017-08-16 Glycotope GmbH Fermentationsprozess
CA2722738C (en) * 2008-05-13 2017-04-25 Glycotope Gmbh Fermentation process
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
EP2153837A1 (en) * 2008-08-14 2010-02-17 Compagnie Gervais Danone Compositions comprising Lactobacillus casei for improving resistance to common infectious diseases
FR2937252B1 (fr) * 2008-10-17 2011-05-20 Pf Medicament Association d'un extrait de sureau et d'une souche de l. paracasei.
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US9056123B2 (en) * 2010-01-08 2015-06-16 Compagnie Gervais Danone Lactobacilli with anti-oxidant action
CN103097513B (zh) * 2010-03-12 2018-01-30 热尔韦·达诺尼公司 用于乳糜泻的乳酸菌
US20130195917A1 (en) * 2010-10-15 2013-08-01 Dorte Eskesen Immunoadjuvant
EP2455092A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
JP6148671B2 (ja) 2011-08-22 2017-06-14 グリコトープ ゲーエムベーハー 腫瘍抗原を保有する微生物
WO2014038929A1 (en) 2012-09-07 2014-03-13 N.V. Nutricia Probiotics for producing antiviral factors
HRP20240756T1 (hr) 2018-05-18 2024-09-13 Daiichi Sankyo Co., Ltd. Anti-muc1-eksatekan antitijelo-lijek konjugat

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05236872A (ja) * 1992-02-27 1993-09-17 Takanashi Nyugyo Kk 乳酸菌含有食品
JP4112021B2 (ja) * 1994-02-16 2008-07-02 明治乳業株式会社 乳酸菌を用いた免疫賦活剤
ES2126962T3 (es) * 1995-01-02 1999-04-01 Gervais Danone Co Fermento lactico, y su uso para la preparacion de productos antidiarreicos.
ID24734A (id) * 1997-08-21 2000-08-03 New Zealand Dairy Board Bakteri asam laktat yang meningkatkan kekebalan
US6699517B2 (en) * 1997-11-28 2004-03-02 Compagnie Gervais Danone Method for preparing food products by fermenting soy milk with streptococcus thermophilus
IT1298918B1 (it) * 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
KR100324441B1 (ko) * 1999-02-08 2002-02-27 이은선 위염, 위궤양, 십이지장궤양 예방을 위한 식품

Also Published As

Publication number Publication date
CN1430518A (zh) 2003-07-16
HUP0302041A3 (en) 2005-11-28
EA005081B1 (ru) 2004-10-28
FR2809312B1 (fr) 2002-07-12
PL201801B1 (pl) 2009-05-29
EP1283714B1 (fr) 2006-07-05
ES2267763T3 (es) 2007-03-16
MA25760A1 (fr) 2003-04-01
HK1055898A1 (en) 2004-01-30
PT1283714E (pt) 2006-11-30
HRP20020935A2 (en) 2005-02-28
ZA200209087B (en) 2004-06-30
WO2001089541A1 (fr) 2001-11-29
NO20025595L (no) 2003-01-22
BG65884B1 (bg) 2010-04-30
PL358408A1 (en) 2004-08-09
CA2410350A1 (fr) 2001-11-29
DK1283714T3 (da) 2006-10-30
NO332369B1 (no) 2012-09-03
DE60121327T2 (de) 2007-07-26
CA2410350C (fr) 2013-04-09
NO20025595D0 (no) 2002-11-21
ATE332143T1 (de) 2006-07-15
EA200201248A1 (ru) 2003-06-26
AR028626A1 (es) 2003-05-14
DE60121327D1 (de) 2006-08-17
AU5643501A (en) 2001-12-03
CN1194707C (zh) 2005-03-30
EP1283714A1 (fr) 2003-02-19
US20040029127A1 (en) 2004-02-12
AU2001256435B2 (en) 2006-06-29
BG107299A (bg) 2003-07-31
IL152980A0 (en) 2003-06-24
CZ303600B6 (cs) 2013-01-02
FR2809312A1 (fr) 2001-11-30
HUP0302041A2 (hu) 2003-09-29
JP2003534284A (ja) 2003-11-18
US7604809B2 (en) 2009-10-20
MXPA02011636A (es) 2003-05-14
SK18272002A3 (sk) 2003-08-05
CZ20024189A3 (cs) 2003-05-14

Similar Documents

Publication Publication Date Title
DK1436380T3 (da) Sammensætning omfattende en lactobacillusstamme samt anvendelser deraf
AR028626A1 (es) Utilizacion de l. casei en composiciones estimuladoras de la inmunidad
TR200101699T2 (tr) Urogenital enfeksiyonların önlenmesi ve tedavisi için ağızdan lactobakilus uygulaması
BR0011038A (pt) Composição farmacêutica ou dietética para uso na prevenção ou tratamento da hiperoxalúria
BR0008912A (pt) Cepas de bactérias do ácido láctico capazes de prevenir a diarréia
BR0314060A (pt) Bactéria probiótica: lactobacillus fermentum
BR9900972A (pt) Uso de uma associação de lactobacilos para a preparação de uma composição para tratamento de vaginoses e vaginites, e composições farmacêuticas assim preparadas.
PT2201955T (pt) Bifidobacterium lactis bb-12 na prevenção primária de doenças atópicas
BR0315209A (pt) Formulações nutritivas que contêm substâncias simbióticas
BR0008920A (pt) Cepas de lactobacillus capazes de prevenirdiarréia causada por bactéria patogênica erotaviroses
NO20014299L (no) Lactobacillus-stammer som forebygger patogene diar±bakterier
IL156490A0 (en) Probiotic compounds derived from lactobacillus casei strain ke01
AR038592A1 (es) Composicion fotoprotectora de la piel administrable por via oral
BR0013110A (pt) Forma oral de administração contendo microorganismos probióticos
BRPI0417825A (pt) métodos para uso de lactobacilli probióticos para animais de estimação
BR0207397A (pt) Cepa de bactéria de ácido láctico e composições comestìveis, drogas e produtos veterinários contendo-a
WO2003039260A3 (en) PROBIOTIC COMPOSITIONS
AU2002349226A1 (en) Lactic acid bacteria and their use for treating and preventing cancer
BR0109496A (pt) Uso de bactéria do ácido láctico para o tratamento de peritonite
EP2124976A4 (en) WAKE-INHIBITION AND ELIMINATION OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS BY MILKY ACID BACTERIA
EE05459B1 (et) Sporogeense Bacillus smithii tvi TBMI12 MSCL P737 ja selle endospooride kasutamine probiootikumina, toidulisandina ning probiootiline kompositsioon
AR025410A1 (es) Metodo para preparar una bacteria s. thermophilus resistente al ataque de por lo menos un bacteriofago
AU5069500A (en) Use of lactic acid bacteria in the preparation of fermented milks for the treatment of depressed immunity levels
ES2169675B1 (es) Producto con propiedades antiinflamatorias para el colon humano.
RU2000103571A (ru) Штамм бактерий pseudomonas fluorescens вкм в-2224д-продуцент витамина в12

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: COMPAGNIE GERVAIS DANONE (FR)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020080108616/RJ DE 11/08/2008.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11M Decision cancelled [chapter 11.13 patent gazette]

Free format text: O PRESENTE PEDIDO TEVE SEU ARQUIVAMENTO NOTIFICADO NA RPI NO 2226 DE 03/09/2013 (DESPACHO 11.5), DE ACORDO COM O ART. 34 DA LPI. NO ENTANTO, O REQUERENTE ATENDEU AOS PRESSUPOSTOS DO ART. 34 DA LPI, TEMPESTIVAMENTE, ATRAVES DA PETICAO NO 018110005044 DE 11/02/2011 (DECLARACAO NEGATIVA). DESTE MODO, ANULO O REFERIDO ARQUIVAMENTO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]